行情

AORT

AORT

Cryolife Inc
NYSE

实时行情|Nasdaq Last Sale

16.41
+0.68
+4.32%
已收盘, 16:02 05/13 EDT
开盘
15.91
昨收
15.73
最高
16.52
最低
15.91
成交量
13.30万
成交额
--
52周最高
31.78
52周最低
15.44
市值
6.60亿
市盈率(TTM)
-40.6188
分时
5日
1月
3月
1年
5年
Further weakness as Artivion (NYSE:AORT) drops 24% this week, taking three-year losses to 48%
Many investors define successful investing as beating the market average over the long term. But in any portfolio...
Simply Wall St. · 3天前
--Needham Trims Artivion's Price Target to $29 From $30, Reiterates Buy Rating
MT Newswires · 05/06 06:37
Artivion Non-GAAP EPS of $0.03, revenue of $77.2M
Artivion press release (NYSE:AORT): Q1 Non-GAAP EPS of $0.03. Revenue of $77.2M (+8.6% Y/Y). For FY22, the company continues to expect constant currency revenue growth of between 9.0% and 11.0%,
Seekingalpha · 05/05 20:46
Artivion Q1 EPS $0.03 Beats $(0.12) Estimate, Sales $77.20M Beat $74.85M Estimate; Sees FY22 Sales Growth 9-11% Year Over Year
Artivion (NYSE:AORT) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.12) by 125 percent. This is unchanged from the same period last year. The company reported quarterly
Benzinga · 05/05 20:38
-- Earnings Flash (AORT) ARTIVION Reports Q1 EPS $0.03, vs. Street Est of $-0.01
MT Newswires · 05/05 16:26
-- Earnings Flash (AORT) ARTIVION Reports Q1 Revenue $77.2M, vs. Street Est of $74.9M
MT Newswires · 05/05 16:21
ArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results will be released on Thursday, May 5, 2022 after the market closes. On that day, the Company wil...
PR Newswire · 04/21 12:25
Artivion to Participate in the 21st Annual Needham Virtual Healthcare Conference
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming 21st Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is schedu...
PR Newswire · 03/31 12:25
更多
暂无数据
了解AORT最新的财务预测,通过AORT每股收益,每股净资产,每股现金流等数据分析Cryolife Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

60.00%强力推荐
20.00%买入
20.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测AORT价格均价为28.20,最高价位35.00,最低价为23.00。
最高35.00
均价28.20
最低23.00
现价16.41
EPS
实际EPS
预期EPS
-0.34-0.18-0.010.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 198
机构持股: 3,590.05万
持股比例: 89.30%
总股本: 4,020.16万
类型机构数股数
增持
37
109.98万
建仓
15
44.75万
减持
52
84.69万
平仓
16
22.94万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
+2.66%
医疗设备和用品
+3.28%
高管信息
Chairman/President/Chief Executive Officer/Director
James Mackin
Chief Financial Officer/Chief Operating Officer/Executive Vice President
D. Ashley Lee
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Jean Holloway
Senior Vice President/Director of Sales/Director of Marketing
John Davis
Senior Vice President
Marshall Stanton
Chief Accounting Officer/Vice President
Amy Horton
Vice President - Operations
Dennis Maier
Vice President/Director of Human Resources
Matthew Getz
Vice President
F. Peter Barthold
Vice President
Andrew Green
Vice President
Rochelle Maney
Lead Director/Independent Director
Jeffrey Burbank
Independent Director
Thomas Ackerman
Independent Director
Daniel Bevevino
Independent Director
Marna Borgstrom
Independent Director
James Bullock
Independent Director
Jon Salveson
Independent Director
Anthony Semedo
暂无数据
暂无数据
AORT 简况
Artivion Inc(Artivion)(原名:CryoLife, Inc.)是一家医疗器械公司。该公司致力于开发各种解决方案,以解决心脏和血管外科医生在治疗主动脉疾病患者时面临的挑战。该公司的四组产品包括主动脉支架和支架移植物、人工心脏瓣膜、冷冻保存的心脏和血管同种异体移植物以及外科密封剂。该公司冷冻保存的心脏和血管同种异体移植组织有助于恢复成人和儿童患者的手术。该公司通过BioGlue产品提供外科密封剂。其外科主动脉瓣置换解决方案包括用于Ross手术的On-X主动脉心脏瓣膜和CryoValve SG肺瓣膜同种异体移植。该公司的二尖瓣解决方案包括用于二尖瓣修复的Chord-X和On-X二尖瓣心脏瓣膜。该公司的心脏和血管辅助解决方案为患者的心脏和血管外科手术提供补充支持。

微牛提供Artivion Inc(NYSE-AORT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AORT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AORT股票基本功能。